IVADINE 7.5 is a prescription cardiovascular medicine containing Ivabradine 7.5 mg, a selective If channel inhibitor specifically designed to manage conditions associated with elevated heart rate. Unlike traditional beta-blockers, Ivabradine lowers heart rate by directly acting on the sinoatrial node, without affecting myocardial contractility, blood pressure, or cardiac conduction.

Elevated heart rate is a significant risk factor in chronic stable angina and heart failure with reduced ejection fraction (HFrEF). By optimizing heart rate, IVADINE 7.5 improves oxygen supply-demand balance in the heart, reduces angina attacks, enhances exercise tolerance, and contributes to better long-term cardiovascular outcomes.

The 7.5 mg formulation is designed for patients requiring a higher dose for effective heart rate control, offering once- or twice-daily dosing convenience for chronic therapy in both hospital and outpatient settings.

Uses

IVADINE 7.5 is indicated for the management of multiple cardiovascular conditions:

1. Chronic Stable Angina

IVADINE 7.5 reduces the frequency of angina attacks in patients with normal sinus rhythm who continue to experience symptoms despite conventional therapy, such as beta-blockers or nitrates.

2. Heart Failure with Reduced Ejection Fraction (HFrEF)

Patients with chronic heart failure and an elevated resting heart rate benefit from Ivabradine’s selective action, which improves ventricular filling time and cardiac efficiency, ultimately enhancing exercise tolerance and reducing hospitalization risk.

3. Adjunct Therapy

IVADINE 7.5 can be used in combination with guideline-directed heart failure therapy, including ACE inhibitors, ARBs, and diuretics, to optimize heart rate and improve overall cardiac function.

4. Management of Elevated Heart Rate

In patients where elevated heart rate contributes to worsening cardiac outcomes, IVADINE 7.5 provides targeted control, improving both symptoms and quality of life.

By targeting the sinoatrial node directly, IVADINE 7.5 offers precise heart rate control without significant blood pressure reduction, making it suitable for patients with hypotension or intolerance to higher doses of beta-blockers.

Benefits

IVADINE 7.5 offers a range of clinical and patient-centered advantages:

1. Selective Heart Rate Reduction

Ivabradine selectively slows the heart rate without negative inotropic or hypotensive effects, differentiating it from conventional beta-blockers.

2. Symptom Relief in Angina

Regular use leads to a significant reduction in angina attacks, decreasing reliance on short-acting nitrates and improving daily functioning.

3. Improved Exercise Tolerance

By optimizing cardiac function, IVADINE 7.5 allows patients to perform daily activities with less fatigue and discomfort, enhancing quality of life.

4. Reduced Hospitalization Risk in Heart Failure

Clinical studies demonstrate that Ivabradine, when added to standard therapy, reduces hospitalization due to worsening heart failure, contributing to better long-term outcomes.

5. Predictable Pharmacokinetics

The 7.5 mg formulation ensures consistent therapeutic effects, making dose adjustment straightforward under medical supervision.

6. Well-Tolerated Therapy

Most side effects are mild and transient, allowing safe and sustained long-term therapy.

These benefits make IVADINE 7.5 an essential part of modern cardiovascular management, particularly for patients with elevated resting heart rates or persistent angina symptoms.

Dosage

The dosage of IVADINE 7.5 should be determined by a healthcare professional, based on the patient’s condition, heart rate, and response to therapy.

Recommended Dosage:

• Typical Starting Dose: One tablet of IVADINE 7.5 mg twice daily.

• Dose Adjustment: Depending on heart rate and tolerability, the dose may be reduced to 5 mg twice daily or maintained at 7.5 mg for optimal control.

• Administration: Tablets should be swallowed whole with water and taken at the same time each day, preferably with meals to maintain consistency.

Special Considerations:

• Monitor heart rate regularly, particularly during therapy initiation or dose adjustment.

• Use caution in elderly patients or those with hepatic impairment.

• Therapy should not be abruptly discontinued, as sudden cessation may worsen symptoms or increase heart rate.

Proper dosing ensures maximum therapeutic benefit while minimizing adverse effects.

Side Effects

IVADINE 7.5 is generally well-tolerated, but some patients may experience side effects related to heart rate reduction.

Common Side Effects:

• Temporary bradycardia (slow heart rate)

• Fatigue or tiredness

• Dizziness or lightheadedness

• Visual disturbances such as transient blurred vision or luminous phenomena (phosphenes)

Less Common but Serious Side Effects:

• Severe bradycardia or syncope

• Heart rhythm abnormalities

• Hypotension in susceptible patients

• Allergic reactions such as rash or swelling

Patients experiencing severe or persistent side effects should seek immediate medical attention. Regular monitoring during therapy allows early detection and management of complications.

Precautions and Warning

Before initiating therapy with IVADINE 7.5, several precautions must be considered:

1. Heart Rhythm Monitoring

Contraindicated in patients with sinoatrial block, severe bradycardia, or sick sinus syndrome, unless a pacemaker is in place.

2. Severe Heart Failure or Hypotension

Use with caution in patients with severe hypotension (BP < 90/50 mmHg) or decompensated heart failure.

3. Liver Impairment

Ivabradine is metabolized in the liver; dose adjustment or close monitoring may be required in hepatic dysfunction.

4. Drug Interactions

Patients should inform their doctor of concurrent medications, especially CYP3A4 inhibitors, which can increase Ivabradine levels and the risk of bradycardia.

5. Pregnancy and Lactation

Use only if clearly indicated, under strict medical supervision.

6. Lifestyle Considerations

Avoid abrupt discontinuation, excessive caffeine, or alcohol, as these may influence heart rate or exacerbate symptoms.

Adherence to these precautions ensures safe and effective therapy.

Conclusion

IVADINE 7.5, containing Ivabradine 7.5 mg, is a modern cardiovascular therapy that provides precise, selective heart rate control. Its unique action on the sinoatrial node allows effective management of chronic stable angina and heart failure with reduced ejection fraction, without the negative inotropic or hypotensive effects associated with beta-blockers.